Related Experiment Videos
Endocrine profiles in tamoxifen-induced conception cycles
Fertility and Sterility
|October 1, 1984
Summary
Tamoxifen (TMX) aided infertile women in conceiving by increasing estradiol during follicular development and progesterone during the luteal phase. This suggests TMX has direct ovarian and luteotropic effects, enhancing fertility.
Area of Science:
- Reproductive Endocrinology
- Pharmacology
Background:
- Infertility affects a significant portion of the reproductive-aged population.
- Tamoxifen (TMX) is a selective estrogen receptor modulator used in breast cancer treatment and sometimes off-label for ovulation induction.
Purpose of the Study:
- To investigate the hormonal profiles during tamoxifen (TMX)-induced conception cycles.
- To elucidate the potential mechanisms of TMX action on folliculogenesis and luteal function in infertile women.
Main Methods:
- Serum hormone levels (follicle-stimulating hormone, luteinizing hormone, estradiol, progesterone) were measured.
- Profiles from 5 TMX-induced conception cycles were compared to 5 normal conception cycles.
- Analysis focused on follicular and luteal phase hormone concentrations.
Main Results:
- Higher estradiol levels were observed during the follicular phase in TMX cycles despite lower FSH and LH.
- Higher progesterone levels were noted on days 6-7 of the luteal phase in TMX cycles.
- Twenty-five infertile women conceived using tamoxifen.
Conclusions:
- Tamoxifen (TMX) may exert a direct ovarian effect, enhancing folliculogenesis and leading to higher estradiol levels.
- TMX might possess a luteotropic influence, potentially supporting the blastocyst stage and increasing progesterone.
- These hormonal changes suggest TMX as a viable option for enhancing fertility in select infertile women.